Regulated
information
December 18,
2017
Breda, the
Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq:
ARGX) a clinical-stage biotechnology company developing a deep
pipeline of differentiated antibody-based therapies for the
treatment of severe autoimmune diseases and cancer, announced today
the closing of its public offering in the United States of
5,106,000 American Depositary Shares (ADSs), at a price of $52.00
per ADS, for gross proceeds of approximately $266 million. This
includes the full exercise of the underwriters' option to purchase
additional ADSs.
Each of the ADSs offered
represents the right to receive one ordinary share, nominal value
of €0.10 per share.
argenx's ADSs are currently listed on the Nasdaq Global Select
Market under the symbol "ARGX," and argenx's ordinary shares are
currently listed on Euronext Brussels.
Cowen and Piper Jaffray & Co.
acted as joint bookrunning managers for the Offering, and JMP
Securities and Wedbush PacGrow acted as co-managers. Kempen &
Co was argenx's advisor in connection with the Offering.
A registration statement relating
to these securities was declared effective by the U.S. Securities
and Exchange Commission (SEC) on December 13, 2017. This
registration statement can be accessed through the SEC's website at
www.sec.gov.
Copies of the final prospectus for
this Offering may be obtained for free from Cowen and Company, LLC,
c/o Broadridge Financial Services, 1155 Long Island Avenue,
Edgewood, NY 11717, Attn: Prospectus Department, by telephone at
(631) 274-2806 or by fax at (631) 254-7140 or from Piper Jaffray
& Co., Attn: Prospectus Department, 800 Nicollet Mall, J12S03,
Minneapolis, MN 55403, or by telephone at (800)747-3924, or by
email at prospectus@pjc.com.
In addition, argenx announced
today the listing of and the commencement of dealings in its
5,106,000 new ordinary shares underlying the ADSs (the New Ordinary
Shares) on the regulated market of Euronext Brussels, effective
today, following Euronext Brussels' approval of argenx's request
for the admission to listing and trading of the New Ordinary Shares
on the regulated market of Euronext Brussels.
This press release is for
information purposes only and does not constitute, and should not
be construed as, an offer to sell or the solicitation of an offer
to buy or subscribe to any securities, nor shall there be any sale
of securities in any jurisdiction in which such offer, solicitation
or sale is not permitted or to any person or entity to whom it is
unlawful to make such offer, solicitation or sale. Reference is
also made to the restrictions set out in "Important information"
below. This press release is not for publication or distribution,
directly or indirectly, in or into any state or jurisdiction into
which doing so would be unlawful or where a prior registration or
approval is required for such purpose.
About
argenx
argenx is a clinical-stage biotechnology company developing a deep
pipeline of differentiated antibody-based therapies for the
treatment of severe autoimmune diseases and cancer. We are focused
on developing product candidates with the potential to be either
first-in-class against novel targets or best-in-class against
known, but complex, targets in order to treat diseases with a
significant unmet medical need. Our ability to execute on this
focus is enabled by our suite of differentiated technologies. Our
SIMPLE Antibody(TM) Platform, based on the powerful llama immune
system, allows us to exploit novel and complex targets, and our
three antibody engineering technologies are designed to enable us
to expand the therapeutic index of our product
candidates.
www.argenx.com
For further
information, please contact:
Joke Comijn, Corporate
Communications Manager
+32 (0)477 77 29 44
+32 (0)9 310 34 19
info@arGEN-X.com
Beth DelGiacco (US IR)
Stern Investor Relations
+1 212 362 1200
beth@sternir.com
Forward-looking Statements
The contents of this announcement include
statements that are, or may be deemed to be, "forward-looking
statements." These forward-looking statements can be identified by
the use of forward-looking terminology, including the terms
"believes," "estimates," "anticipates," "expects," "intends,"
"may," "will," or "should." By their nature, forward-looking
statements involve risks and uncertainties and readers are
cautioned that any such forward-looking statements are not
guarantees of future performance. argenx's actual results may
differ materially from those predicted by the forward-looking
statements as a result of various important factors, including
argenx's expectations regarding its the inherent uncertainties
associated with competitive developments, preclinical and clinical
trial and product development activities and regulatory approval
requirements; argenx's reliance on collaborations with third
parties; estimating the commercial potential of argenx's product
candidates; argenx's ability to obtain and maintain protection of
intellectual property for its technologies and drugs; argenx's
limited operating history; and argenx's ability to obtain
additional funding for operations and to complete the development
and commercialization of its product candidates. A further list and
description of these risks, uncertainties and other risks can be
found in argenx's SEC filings and reports, including in the final
prospectus related to argenx's U.S. public offering filed with the
SEC pursuant to Rule 424(b) of the Securities Act of 1933, as
amended, as well as subsequent filings and reports filed by argenx
with the SEC. Given these uncertainties, the reader is advised not
to place any undue reliance on such forward-looking statements.
These forward-looking statements speak only as of the date of
publication of this document. argenx undertakes no obligation to
publicly update or revise the information in this press release,
including any forward-looking statements, except as may be required
by law.
Important information
No public offering will be made and no one has
taken any action that would, or is intended to, permit a public
offering in any country or jurisdiction, other than the United
States, where any such action is required, including in the
European Economic Area. In the European Economic Area, the
transaction to which this press release relates will only be
available to, and will be engaged in only with, qualified investors
within the meaning of Directive 2003/71/EC (together with any
applicable implementing measures in the relevant member state of
the European Economic Area and as amended, including by Directive
2010/73/EU, to the extent implemented in the relevant member
state).
In addition, in
the United Kingdom, the transaction to which this press release
relates will only be available to, and will be engaged in only
with, investment professionals falling within Article 19(5) of the
Financial Services and Markets Act (Financial Promotion) Order
2005, as amended (the Order), persons falling within Article
49(2)(a) to (d) of the Order, and other persons to whom this
announcement may lawfully be communicated (all such persons
together being referred to as "relevant persons"). The securities
referred to herein are only available to, and any invitation, offer
or agreement to subscribe, purchase or otherwise acquire such
securities will be engaged in only with relevant persons. Any
person who is not a relevant person should not act or rely on this
communication or any of its contents.
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: argenx SE via Globenewswire
argenx (NASDAQ:ARGX)
Historical Stock Chart
From Apr 2024 to May 2024
argenx (NASDAQ:ARGX)
Historical Stock Chart
From May 2023 to May 2024